Resource Use and Cost of Alzheimer’s Disease in France- 18-Month Results from the GERAS Observational Study

Mar 1, 2018, 00:00
10.1016/j.jval.2017.09.019
https://www.valueinhealthjournal.com/article/S1098-3015(17)33563-5/fulltext
Title : Resource Use and Cost of Alzheimer’s Disease in France- 18-Month Results from the GERAS Observational Study
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33563-5&doi=10.1016/j.jval.2017.09.019
First page : 295
Section Title : ECONOMIC EVALUATION
Open access? : No
Section Order : 7

Background

There is little longitudinal data on resource use and costs associated with Alzheimer’s disease (AD) in France.

Objectives

To evaluate resource use and societal costs associated with AD in a French cohort of patients and their caregivers and the effect of patient cognitive decline on costs over an 18-month period.

Methods

Community-dwelling patients with mild, moderate, or moderately severe/severe AD dementia (n = 419) were followed-up for 18 months. Total societal costs were estimated by applying 2010 unit costs to resource use, including outpatient visits, hospital days, institutionalization, and caregiver hours. Cognitive function was assessed by Mini-Mental State Examination scores.

Results

Mean cumulative total costs over the 18-month period were €24,140 for patients with mild AD dementia, €34,287 for those with moderate AD dementia, and €44,171 for those with moderately severe/severe AD dementia (P mean monthly caregiver time increased at each time point over the 18 months in each severity group.

Conclusions

Increasing severity of AD dementia in France is associated with increased use of resources as well as increased total societal and patient costs; informal care was the greatest cost contributor. Clinically meaningful cognitive decline is associated with significantly increased costs.

Categories :
Tags :
  • Alzheimer’s disease
  • costs
  • France
  • resource use
Regions :
ViH Article Tags :